Background: Regulatory agencies have concluded that sodium glucose cotransporter 2 (SGLT2)
Results: FAERS contained 259 reports of acidosis (including 192 reports of ketoacidosis) for
SGLT2 inhibitors compared with 477 reports of acidosis for DPP4 inhibitors (including 71 reports of ketoacidosis). Based on estimated patient exposure, the overall risk of developing acidosis was 14-fold higher for SGLT2 inhibitors. Among 51 SGLT2 inhibitor-related reports with quantifiable metabolic information, 20 cases occurred in patients with type 1 diabetes (T1D), 25 in type 2 diabetes (T2D), and 6 in patients with unspecified type of diabetes. After excluding patients with T1D and focusing on patients identified as having T2D, we estimate that SGLT2 inhibitors were associated with~7-fold increase in developing acidosis. Seventy-one percent had euglycemic ketoacidosis.
Conclusions:
Our results support the FDA 0 s warning that SGLT2 inhibitors lead to ketoacidosis, as evidenced by an increased reporting rate for acidosis above that in a comparator population treated with DPP4 inhibitors. 1,2 Preliminary data also suggests that these 2 drugs may slow the progression of diabetic kidney disease. 2, 3 Cardiovascular outcome studies are currently underway for dapagliflozin. 4 During the time that SGLT2 inhibitors have been marketed in the United States, the FDA has identified several adverse effects of these drugs. The FDA approved Prescribing
Information states that canagliflozin causes loss of bone mineral density and increases the risk of bone fractures and amputations. 5 Data supporting these side effects have been reported in the peerreviewed literature. 2, 6, 7 While the Prescribing Information for the 3 marketed SGLT2 inhibitors (canagliflozin, dapagliflozin, and empagliflozin) cites an increase in the risk of ketoacidosis, the detailed data supporting these statements from the FDA have not yet been published in the peer-reviewed literature. Nevertheless, a randomized double-blind study of off-label use in type 1 diabetes (T1D) has provided convincing evidence that canagliflozin increases the risk of ketone-related adverse events from 0% (placebo) to 9.4%
(canagliflozin, 300 mg). 8 Based on published data, the risk appears to be smaller when these drugs are used for the approved indication of
: "The incidence of DKA in T2D treated with SGLT-2 inhibitors does not appear to exceed the low levels occurring in the general diabetes population." In other words, more than a year after FDA issued the first warning that SGLT2 inhibitors increase the risk of ketoacidosis, 2 leading professional organizations of clinical endocrinologists questioned the basic premise that the incidence of ketoacidosis is increased among patients taking this class of drugs.
We conducted the present study to address concerns expressed in the AACE/ACE position statement-for example, by comparing rates of ketoacidosis in SGLT2 inhibitor-treated patients to a comparator group (ie, patients treated DPP4 inhibitors). Our analysis is entirely consistent with and supports the FDA 0 s conclusion the there is a greater incidence of reports of acidosis among patients treated with SGLT2 inhibitors as compared with the incidence observed in a com- events. Alogliptin (representing only~0.3% of sales) was approved in Japan substantially before approval in the United States. Because of the possibility that physicians in different countries might have different practices with respect to reporting adverse events to the FAERS database, we excluded alogliptin-associated reports from our analysis.
By focusing on sitagliptin and saxagliptin, our analysis covers drugs representing the vast majority of the DPP4 market (97-98%) and avoids the impact of confounding factors associated with drugs taken by relatively few patients (2-3%) prior to May, 2015.
Although it would be most informative to know the precise number of patients experiencing ketoacidosis events, the FAERS database is limited to case reports (hereby termed "reports") of ketoacidosis events. The MedDRA® defines the relationship between an event and a (case) report as, "the total number of events may be greater than the number of cases because a case may describe more than one event To estimate the risk associated with a specific drug, it is necessary to relate the number of cases to the number of patient-years of exposure to drug. However, data on the total number of patients treated with specific drugs are not freely available in the public domain. Thus, we employed data on drug sales as a surrogate index of patient exposure. We hypothesize that total sales of drugs are roughly proportional to the number of treated patients inasmuch as the list prices are similar for all drugs included in this analysis. We acknowledge that there can be substantial variation in the actual prices paid by individual patients for the same drug. However, for the purpose of our analysis, we implicitly assume that the patient-to-patient variation may be similar in magnitude among the various SGLT2 inhibitors and DPP4 inhibitors. We obtained data on the value of sales from companies 0 financial statements from each company 0 s website (see Online Supplement 2).
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We obtained data on drug prices from the internet (www.goodrx.com).
| RESULTS
The FAERS database contained almost 8,000 individual reports on adverse events related to the 3 SGLT2 inhibitors currently on the US 11 and our analysis may be explained by differences in selection criteria.
Of the 51 cases, T1D accounted for 20 (39%) and T2D for 25 assumptions, the corrected analysis provides a lower estimate for the SGLT2 inhibitor-associated risk of acidosis in T2D patients-ie, a 7-fold (rather than a 14-fold) increase in risk.
It is also noteworthy that 74% of the reports of SGTL2 inhibitorassociated reports of acidosis were designated as "ketoacidosis" compared with only 15% of DPP4 inhibitor-associated reports. This raises the possibility that a significant fraction of DPP4 inhibitor-associated cases of acidosis may represent cases of lactic acidosis rather than ketoacidosis.
| DISCUSSION
The present analysis confirms the FDA 0 s conclusion that SGLT2 inhibitors increase the risk of ketoacidosis, and extends the previously avail- patients would be 51% lower-ie,~7-fold increased risk based on all cases of acidosis in T2D (instead of 14-fold). These estimates approximately double the previously reported~3-fold increased risk. 9 Widespread public awareness of the potential risk for ketoacidosis was generated by the first FDA announcement in May 2015. By ending our analysis in May 2015 and by analysing the data according to both search terms "acidosis" and "ketoacidosis", we attempted to minimize bias that could have been introduced-eg, by an increased number of reports generated by health care providers who were sensitized to the issue or, by contrast, by a decreased number of reports due to a perceived lack of novelty. In addition, there was an approximate 2-year overlap in the reporting period for both drug classes. During this time, published data on the risk had not become available; thus, clinicians probably did not suspect that these 2 classes of drugs would have different risks for treatment-emergent ketoacidosis. Therefore, it is reasonable to assume that physicians would be equally likely to report cases of ketoacidosis-regardless of whether a patient was being treated with a DPP4 inhibitor or an SGLT2 inhibitor.
In order to estimate reporting rates for acidosis, it is necessary to relate the number of reports to the number of patient-years of exposure. Unfortunately, companies do not include data on the numbers of patients who take their drugs. However, government regulations require companies to disclose data on drug sales if the sales are large enough to be of significance to the companies 0 financial health. We have used total drug sales as an index to estimate patient years of exposure. During the timeframe under analysis, sitagliptin and canagliflozin account for~89% and~93% of total sales for the DPP4 inhibitor and SGLT2 inhibitor classes, respectively, and sales of these 2 drugs are the major determinants of total sales for the 2 classes of drugs. Both drugs have similar list prices (~$4000 per year). For most patients, the actual selling price would be discounted relative to the list price. Our analysis implicitly assumes that the average discounted price would be similar for drugs in both classes. Although we recognize that there may be some degree of variation in the size of discounts among the various drugs in these 2 classes, it seems unlikely that the variation is sufficient to account for the estimated differences in incidences of reported cases of acidosis. For example, if the average selling price for sitagliptin were discounted by 50%, then one would need to assume that the average selling price for canagliflozin would have been discounted by 93% to account for the 7-fold difference in the incidence estimates. Such a large difference in price discount seems unlikely for 2 first-in-class diabetes drugs such as sitagliptin vs canagliflozin.
Erondu et al suggested that 50% of cases of diabetic ketoacidosis occurred in patients with anti-GAD65 autoantibodies, who are presumed to have adult onset autoimmune mediated diabetes rather than non-autoimmune T2D. 9 Likewise, others 23 have stated the risk for ketoacidosis with SGLT2 inhibitors "may be increased in long-standing T2D patients with marked β-cell insufficiency or in latent autoimmune diabetes in adults with rapid evolution toward T1D". From a purely academic perspective, this is an important finding, which has potential to give insight into the mechanisms of the pathogenesis of SGTL2
inhibitor-induced diabetic ketoacidosis. However, in order to translate this into a clinically relevant risk management strategy, it would be necessary to routinely measure anti-GAD65 antibodies or c-peptide levels prior to prescribing SGLT2 inhibitors. This analysis estimates that SGLT2 inhibitors are associated with an~7-fold increase in risk of acidosis in type 2 diabetic patients, which is approximately double the 2-fold to 4-fold increase in the numerical imbalance reported for canagliflozin 9 and empagliflozin. 1 It is not entirely surprising that the risk might be somewhat higher in real world practice than observed in formal clinical studies in which patients are highly screened and have especially good access to skilled clinical care. Moreover, we acknowledge that our use of a surrogate index for patient exposure does not provide the same degree of certainty that is available in a randomized controlled trial. In addition, it is possible that in real-world practice, there may be differences between patients who receive DPP4 inhibitors vs SGLT2 inhibitors. Nevertheless, we are reassured that our estimates of the increased risk are in the same "ball park" as the published real world experience with canagliflozin and empagliflozin.
Plausible biological mechanisms for the increased risk of ketoacidosis include increased glucagon levels, 24 possibly mediated by a direct effect on pancreatic alpha-cells. 25 Given the role of glucagon in regulating hepatic ketogenesis, SGLT2 inhibitor-induced glucagon secretion would be predicted to increase serum ketone body concentrations. Other contributing factors may include the net negative glucose balance, leading to a shift away from glucose oxidation, thereby promoting fatty acid oxidation, and ketogenesis which increases circulating ketone bodies. [26] [27] [28] Furthermore, it is now well established that SGLT2 inhibitors elevate levels of circulating ketone bodies in patients with type 2 diabetes (T2D). 26, 28, 29 Moreover, in recent studies with luseogliflozin, it has been demonstrated that a low carbohydrate diet exacerbates the SGLT2 inhibitor-induced increase in circulating ketone body levels. 30 Although the degree of ketonemia did not reach levels sufficient to cause major disturbances in acid-base balance, it seems plausible that this degree of druginduced ketosis might predispose patients to develop overt ketoacidosis-especially in the presence of an independent precipitating factor such as infection or the stress associated with surgery.
Additional factors have potential to introduce confounders with respect to our estimates of the reporting rate expressed as a function of total sales for a drug. For example, it is theoretically possible that susceptible patients might experience drug-induced ketoacidosis early during the course of receiving SGLT2 inhibitor therapy. If an episode of ketoacidosis were to lead to discontinuation of the drug, this has potential to provide powerful selection such that patients receiving long-term therapy would tend to have low susceptibility to develop ketoacidosis. However, as reported by Fadini et al, 15 reports of ketoacidosis can occur after any duration of SGLT2 inhibitor use. This observation suggests that any differences between short-term vs longterm therapy is unlikely to introduce significant bias in occurrence of ketoacidosis events or ascertainment of reports. Additionally, with the increased public awareness of SGLT2 inhibitor-induced ketoacidosis, it is plausible that physicians were more likely to test for ketonuria or ketonemia in patients on SGLT2 inhibitor therapy.
We have relied on the reports for diagnosis of T1D vs T2D. Furthermore, we have not attempted to distinguish latent autoimmune diabetes of adults (LADA) from more typical T2D. Although it is possible that some of the patients identified as T2D might have had autoimmune disease, nevertheless, we are following the diagnosis they received in routine clinical practice. Conversely, 3 of the 20 patients diagnosed as T1D were receiving metformin. We have implicitly assumed that these 3 patients were indeed T1D patients receiving metformin off-label just as they were receiving SGLT2 inhibitors off-label. Nevertheless, if they were misclassified and should have been diagnosed as T2D, this would have the effect of increasing the number of ketoacidosis reports in T2D patients.
FDA has required labelling for all members of the SGLT2 inhibitor to indicate a risk for ketoacidosis. Indeed, the data in the FAERS database are consistent with the inference that it is a class effect. This contrasts with respect to certain other adverse effects (ie, bone loss, fracture, and amputations) where the labelling is currently restricted to canagliflozin. While all 3 approved SGLT2 inhibitors share similar C-glucoside chemical structures, it is possible that there could be some degree of differentiation within the class. For example, in a head-tohead trial, approved doses of canagliflozin demonstrate greater efficacy than dapagliflozin. 31 It is possible that the observed difference is explained by the fact that the highest approved dose of canagliflozin is at the upper plateau of the dose-response curve whereas the highest approved dose of dapagliflozin achieves only sub-maximal efficacy.
Further, it is possible that the approved SGLT2 inhibitors might be differentiated with respect to selectivity for other SGLT-family members (eg, SGLT1, SGLT3, and SGLT4).
It can be challenging for Regulatory Agencies, including the FDA, to detect safety signals in pre-approval clinical trials, which typically include comparatively healthy patients treated for relatively short times (6-12 months). In addition, phase 3 studies are generally too small to provide compelling statistical evidence to detect an uncommon safety signal (eg, with an incidence of ≤1:1000), particularly because safety endpoints are rarely pre-specified. Nevertheless, the FAERS database provides an opportunity to evaluate post-marketing "real-world" cases. While FAERS faces its own challenges, including the well-known limitation in the ability to define a "real incidence", it is an important tool to identify safety risks. In light of public interest in the benefit:risk profiles for approved drug-especially drugs as widely used as SGLT2 inhibitors-it is useful to provide insight into the data that support FDA 0 s safety evaluation. 32 The Institute of Medicine report on drug safety 33 identifies challenges in all aspects of drug review and highlights that the FDA is limited in its ability to take "systematic approach to identify possible pre-marketing drug-safety problems and translate them into highquality post-marketing studies," but depends on requests to sponsors to conduct expensive post-approval trials. 34 The tools (eg, FAERS) to detect post-marketing safety signals are dependent on spontaneous reporting, which does not necessarily provide data of the highest quality. Troglitazone, the first thiazolidinedione approved in the United States proved to be hepatotoxic post-approval and was subsequently withdrawn. Likewise, thiazolidinedione-related fractures required time to develop due to the inherent nature of bone physiology. 35, 36 More recently, considerable public concern focused on a debate as to whether or not DPP4 inhibitors cause pancreatitis, which was complicated to tease out in the post-marketing system. 37 The FDA is to be commended for its leadership in identifying safety concerns for this new class of drugs, and also for communicating concerns to physicians and patients. Nevertheless, once FDA has communicated its conclusions, this causes stakeholders to ask questions about the nature and the strength of the evidence supporting those conclusions. Although the FAERS database contains highly relevant data, that database is not freely accessible online. We are grateful that FDA has provided us with the reports, thereby enabling us to analyse the data and make our analysis available in the peer-reviewed literature. 
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